Skip to content

Coagulation in Acute Aortic Dissection

Impact of Anticoagulation Management on Thrombin Generation During Surgery for Acute Aortic Dissection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05484830
Acronym
CAAD
Enrollment
26
Registered
2022-08-02
Start date
2022-11-01
Completion date
2024-12-15
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Aortic Dissection, Coagulation Disorder

Brief summary

Acute aortic dissection (AAD) involving the ascending aorta (Stanford classification type A) remains a life-threatening disease. Excessive perioperative bleeding requiring massive transfusion of allogeneic blood products, and surgical reexploration remain major challenges in these patients. Previous research has indicated that patients with AAD show pronounced haemostatic alterations prior to surgery which are aggravated during major aortic surgery with cardiopulmonary bypass and hypothermia full heparinization. Intensified anticoagulation management guided by heparin dose response (HDR) calculation, and repeated measurement of heparin concentration may be more effective than standard empiric weight-based heparin and protamine management monitored by activated clotting time (ACT) measurements to suppress thrombin generation during surgery for AAD. This randomized controlled clinical trial compares the impact of two recommended anticoagulation management strategies during surgery for AAD including deep hypothermia on activation of coagulation: Heparin/protamine-management based on HDR-titration by means of HMS Plus® versus current institutional standard (HDR- versus ACT-approach). Primary endpoint is thrombin generation as measured by early postoperative prothrombin fragment 1+2 (F1+2). Secondary endpoints are other markers of coagulation and fibrinolysis as well as clinical outcome.

Detailed description

Hypotheses: Primary: HDR-approach is superior to ACT-approach in terms of suppressing thrombin generation after emergent surgery for acute aortic dissection (Stanford type A). Secondary: HDR-approach is superior with regard to * early postoperative haemostatic capacity * requirement of blood product transfusion and haemostatic agents * postoperative bleeding Design: Investigator-initiated, single-site, parallel-group (1:1), prospective, randomized, partially double-blinded trial in patients undergoing emergent surgery for acute aortic dissection comparing two heparin management strategies with superiority design. Prior to randomization, patients are stratified according to preoperative organ dysfunction and anticoagulation therapy. Acute research study design as patients with acute aortic dissection are considered incompetent according to the Danish Research Ethics Committees definition. Deferred consent by the competent patient or her/his proxy (next of kin) and an independent physician) is used. 26 consecutive patients undergoing emergent surgery for acute aortic dissection (Stanford type A) are randomized 1:1 into the following heparin management strategies with an ACT target of 480 seconds: * Individualised HDR-approach * Conventional ACT-approach No interim analysis. A sub-study to compare cost-benefit of both strategies is planned.

Interventions

PROCEDUREIndividualized HDR-approach

Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve. If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required.

PROCEDUREConventional ACT-approach

Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA). Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.).

Sponsors

Ivy susanne Modrau, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Treatment group allocation cannot be concealed for the operating team, but participants, other members of the treatment team, laboratory personnel and other practitioners administering postoperative care as well as outcome assessors will be blinded regarding the allocation.

Intervention model description

Investigator-initiated single-site paralle-group (1:1) prospective, randomized, partially double-blinded trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Emergent Acute Aortic Dissection with cardiopulmonary bypass * Incapable of providing informed consent

Exclusion criteria

* History of congenital coagulation disorder (haemophilia) * Previous open cardiac surgery * Death during induction of anaesthesia

Design outcomes

Primary

MeasureTime frameDescription
F1+2up to 2 days after surgeryProthrombin fragment 1+2 (pmol/L)

Secondary

MeasureTime frameDescription
Protocol violationimmediately after surgeryProtocol violation (yes/no)
Mortalityup to 90 days after surgeryAll-cause mortality
Stroke30 days after surgeryStroke (yes/no)
Myocardial infarction30 days after surgeryPerioperative myocardial infarction (yes/no)
Recombinant FVIIa24 hours after surgeryAdministration of Recombinant FVIIa
2. Closure30 days after surgerySecondary closure
TATup to 2 days after surgeryThrombin-Antithrombin Complex (ug/L)
ETPup to 2 days after surgeryEndogenous Thrombin Potential (nmol/L x min)
Thrombin timeup to 2 days after surgeryHigh-dose thrombin time (sec)
Antithrombinup to 2 days after surgery(kIU/L)
D-dimerup to 2 days after surgeryD-dimer (mg/L)
Clot lysisup to 2 days after surgeryClot lysis
Heparin sensitivityprior to surgeryHeparin sensitivity (slope)
Heparin (total)immediately after surgeryTotal amount of heparin
Protamin (total)immediately after surgeryTotal amount of protamin
Ratioimmediately after surgeryProtamin/heparin ratio
Drain output48 hours after surgeryTotal mediastinal drain output (ml)
Blood cell-saverimmediately after surgeryVolume of blood processed in cell-saver (mL)
Blood loss spongesimmediately after surgeryGravimetric estimation of intraoperative blood loss (calculation based on the change between dry and blood-soaked sponges, accounting for irrigation) in mL
Blood tranfusion48 hours after surgeryTranfusion of blood products (units): Red blood cells, fresh frozen plasma, platelet concentrates
Fibrinogen24 hours after surgeryAdministration of fibrinogen concentrate (mg)
Reoperation for bleeding30 days after surgeryReexploration for bleeding (yes/no)
PCC24 hours after surgeryAdministration of prothrombin complex concentrate (Octaplex) (IU)
AT concentrate24 hours after surgeryAdministration of Antithrombin concentrate (IU)
Cryoprecipitate Plasma24 hours after surgeryAdministration of cryoprecipitate plasma
Renal30 days after surgeryRequirement of continuous renal replacement therapy (yes/no)
Low cardiac output syndrome30 days after surgeryLow cardiac output syndrome requiring inotropics or mechanical support (yes/no)
Vascular malperfusion30 days after surgeryVisceral og peripheral vascular malperfusion requiring surgical or percutaneous intervention
Intraop. coagulationImmediately after surgeryClinical signs of coagulation during CPB (yes/no)
Length of surgery30 days after surgeryminutes
Length of stay ICU30 days after surgerydays
Length of hospitalization30 days after surgeryHospitalization (days)
Resistanceimmediately after surgeryHeparin resistance

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026